KRISANI BIO SCIENCES PVT. LTD.

Size: px
Start display at page:

Download "KRISANI BIO SCIENCES PVT. LTD."

Transcription

1 KRISANI BIO SCIENCES PVT. LTD. Flat B2, 2 nd Floor, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad, Telangana kkr@krisanibio.com. URL: Contact Number:

2 Overview: Krisani Biosciences is pioneering in rapidly and cost effectively design, develop, and commercialize best-in-class innovative therapies for the treatment of Copper toxicity (Wilson s disease), Non-Alcoholic Steatohepatitis (NASH), Neuropathic Pain, Cardiovascular Diseases, Cystinosis, Huntington's disease and Hepatic Disorders; which can provide multiple benefits to patients, caregivers, and consumers. Using our proprietary technologies was able to deliver unique therapeutic molecules with enhanced safety and efficacy. The resulting new molecular entities (NME) provide competitive advantage through product and technology driven multiple layers of intellectual property protection such as patents, trademarks and know-how; in addition to mitigating risks in various stages of development and lowering regulatory hurdles.

3 Business Model: KrisaniBio is an innovative biopharmaceutical company with a value driven sustainable business model with highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are committed to developing therapeutic products that we elieve best- in-class with the potential to be more effective and safer products than the current standard of care or other products in development. Our strategic approach to drug development builds on internally and externally generated knowledge to identify and develop proprietary and highly differentiated products, as well as enables the company to limit development risks and costs. By applying our distinctive technologies and capabilities, and by utilizing an expeditious approach where possible to minimize development risk and costs, we believe that we can create substantial value while being very cost effective. Krisani Biosciences is focused to rapidly and cost-effectively design, develop and out-license or collaboratively develop products by strategic alliances or partnerships. Design, protection of the associated intellectual property and development work will be carried out in Krisani Biosciences Private Limited. After successful completion and validation of early stage proof-of-concept studies, Krisani Biosciences leverages its assets for strategic collaboration or partnering with multinational pharmaceutical companies to further develop and recognize value or out-license the clinical candidate and set royalties and milestones, thereby meeting projected revenues. By maintaining a lean infrastructure, and working collaboratively with others, including leading academic researchers, clinical centers, contract research organizations, and contract manufacturing organizations, we are able to efficiently and cost effectively advance multiple programs in parallel. As the product development programs at Krisanibio continues to advance and mature, the company intends to establish strategic alliances and collaborations in certain areas with leading pharmaceutical and medical device companies. The primary objective of such partnerships is to accelerate product development efforts, and to maximize stakeholder value.

4

5 Research and Development: KrisaniBio's R&D has built one of the strongest and broadest pipelines of potential new candidates. We believe the pipeline has the potential to deliver value to patients and payers and improve rates of financial return on our R&D investment. The primary goal of our R&D function is to appropriately progress our pipeline products safely and efficiently to deliver innovative new medicines. KrisaniBio s has a portfolio of products in the pipeline. The company allocates its R&D investment with reference to the potential returns available from its target therapeutic markets and the technical and commercial aspects, those factors are reviewed at each phase of the development process and are central in the decision to proceed to the next stage. At the centre of this strategy, we will focus our molecules R&D and investments in Neuroscience Pain (Market potential: $29.8 Billion); Neurodegenerative Disorders ($19 Billion); Hepatology-($9 billion) and Cardiovascular Diseases ($116 Billion). KrisaniBio's pipeline is rich in Preclinical and first in human entries aimed at important unmet medical needs such as Copper toxicity, NASH, Neuropathic Pain; Liver Cirrhosis; Hypertriglyceridemia; Oncology, Cystinosis and Huntington's Disease. With biomedical science Advancing on all fronts, we are aiming to work more collaboratively with global clinical research and development organizations and other pharmaceutical and biotech companies in ways that allow us to share risk and gain access to new knowledge and technologies.

6 Intellectual Property It is our policy to try to obtain patents on commercially important, protectable inventions discovered or developed through our R&D activities. Patent protection for new active ingredients is available in major markets and patents can also be obtained for new drug formulations, manufacturing processes, medical uses and devices for administering products. Krisani Biosciences applies its proprietary drug discovery platform to identify novel product candidates in a number of disease areas, including Wilson's disease, NASH, Cardiovascular Diseases, Neuropathic Pain and Neurodegenerative diseases. By applying our proprietary design platform, we have discovered and advanced into pre-clinical trials a portfolio of three product candidates targeting multiple diseases. To-date, the company is currently working on 5 therapeutic areas and had granted 12 international and national patents. To-date, the company has filed one patent application on the novel diagnostic technology and its applications in multiple disease areas with the United States Patent and Trademark Office (USPTO) and Indian Patent Office (IPO).

7 Application Number Title Patent No. / Status US US A1 US A ,6 Xylidine Derivatives for the treatment of Pain Compound, Composition and uses thereof for the treatment of Hypertriglyceridemia Compound, Composition and uses Thereof(Cystinosis) Compound, Compositions, Formulations and their uses thereof Compound, Compositions, Formulations and their uses thereof US B2 GRANTED US B1 GRANTED US B2 GRANTED Japan Israel Compound, Compositions, Formulations and their uses in the treatment diseases related to copper retention or Hepatic Disorders Compound, Compositions, Formulations and their uses thereof Australia European PO Cysteamine Derivatives and their use in the treatment of NASH (FR) derives Cysteamine ET LEUS utilisation DANS LE treatment DESTEATOPATHIES NON ALCOOLIQUES Japan Cysteamine Derivatives and their use in the treatment of NASH Australia Cysteamine Derivatives and their use in the treatment of NASH (FR) derives Cysteamine ET LEUS utilisation DANS LE treatment DESTEATOPATHIES NON ALCOOLIQUES European PO Cysteamine Derivatives and their use in the treatment of NASH Method and System for Prognosis and Treatment of Diseases using Portfolio of Genes Israel Singapore

8 Pipeline Profile: KB-HD-01: Wilson s disease: A novel prodrug and a novel Copper metal chelator with Significant Superior Pharmaceutical Profile compared to the marketed drugs. Potent Copper Chelator cum Antioxidant Lead and has better Drug Profile than D-Penicillamine with Neuroprotective Properties. Presently chemical synthesis completed and preclinical data is encouraging towards proof of concept studies. KB-GE-001:Non-Alcoholic Steatohepatitis (NASH): A novel Co- drug for liver cirosis and exhibits multiple fold activity than the marketed drugs. Chemical synthesis completed and preclinical work under progress KB-CN-01: Neuropathic Pain: A novel prodrug of a local anesthetic that alters signal conduction in neurons by blocking the fast voltage gated sodium (Na+) channels in the neuronal cell membrane; Longer duration of action with enhanced pharma cokinetics, safety and efficacy; Enhanced neural blood flow, conduction and glucose transport. Currently in the advanced Pre-clinical stage. The product portfolio has the potential for the treatment of Diabetic Neuropathy, Post-Herpetic neuralgia, Chronic Pain, Spinal Cord Injury and Peripheral Neuropathy. A US Patent has been granted US B2 in the Month of October KB-CV-001: Hypertriglyceridemia: A novel new molecular entity (NME) of Eicosapentaenoic acid. KB-CV-001 is an ULTRA-PURE form of EPA (Eicosapentaenoic acid) in an ESTER form and when compared to the US-FDA recently approved entity, Amarin Plc sepa ester (VASCEPA) product which claims to have above 96% pure EPA Ester only, whereas, KB-CV-001 EPA analytical purity was found to be 99% and has a greater potential. KB-CV-001is also a derivative of an endogenous compound, 2-aminoethanethiol and is a Chemically Highly Stable compound. KB-ND-01: Huntington s disease (Orphan category): A novel prodrug of Potent Trans glutamase inhibitor, Neuroprotection by increasing brain derived neurotrophic factor (BDNF) levels, Long duration of action with enhanced pharmacokinetics, tolerability, safety and efficacy, Potential to penetrate through Blood-Brain Barrier and stabilizes the neural membrane. Currently in the advanced Pre-clinical stage. The product portfolio has also the potential for the treatment of Nephropathic Cystinosis, Hypertriglyceridemia and Non- alcoholic Steatohepatitis (NASH).

9 Creating a successful and sustainable business is about more than financial results. We place great importance not just on what we achieve but on how we achieve it. Running a responsible, values-based business is embedded in our strategy.

Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications

Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning

More information

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics

More information

Valuing and Licensing Intellectual Property. Richard Williams

Valuing and Licensing Intellectual Property. Richard Williams c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations

More information

Theranexus files its registration document as part of its planned Initial Public Offering (IPO) on the Euronext Growth market in Paris

Theranexus files its registration document as part of its planned Initial Public Offering (IPO) on the Euronext Growth market in Paris This press release cannot be published, transmitted or distributed, directly or indirectly, in the United States, South Africa, Canada, Australia or Japan. This press release does not constitute an offer

More information

Addressing attrition in neurosciences. Dr Ismail Kola Head UCB NewMedicines

Addressing attrition in neurosciences. Dr Ismail Kola Head UCB NewMedicines Addressing attrition in neurosciences Dr Ismail Kola Head UCB NewMedicines Disclaimer and safe harbour Forward-looking statements: This presentation contains forward-looking statements based on current

More information

Voyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies

Voyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat

More information

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215

More information

Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)

Agios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals?

McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals? McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals? Alexia Cesar, Philip Ma, Navjot Singh, Jeff Smith What's Driving the Recent Surge in New Drug Approvals? In 2012, the

More information

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days

Together, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants

More information

Idorsia Company Profile

Idorsia Company Profile Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has

More information

INITIATOR PHARMA: Q3 REPORT 2017

INITIATOR PHARMA: Q3 REPORT 2017 INITIATOR PHARMA: Q3 REPORT 2017 Initiator Pharma A/S, a Danish Biotech Company developing a novel treatment of Erectile Dysfunction. Financial Highlights Initiator Pharma A/S is a Danish registered company,

More information

Almac Overview.

Almac Overview. Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide

More information

LA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES

LA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES LA RICERCA TELETHON PER LE MALATTIE RARE TELETHON RESEARCH ON RARE DISEASES Francesca Pasinelli Direttore Generale 3 Congresso Nazionale SIFaCT Roma, 9 ottobre 2015 About Telethon Fondazione Telethon is

More information

A unique Collaborative Model for the Discovery of New Therapeutic Approaches

A unique Collaborative Model for the Discovery of New Therapeutic Approaches A unique Collaborative Model for the Discovery of New Therapeutic Approaches THE INNOVATION GAP OPEN INNOVATION TO ADDRESS THE LACK OF PRODUCTIVITY OF BIOPHARMACEUTICAL RESEARCH A PRE-COMPETITIVE PHARMA

More information

Management Discussion and Analysis for the Second quarter of FY

Management Discussion and Analysis for the Second quarter of FY Management Discussion and Analysis for the Second quarter of FY 2016 17 Revenue Figures Consolidated (Rs. In Millions) Average conversion rate in Q2 FY 2016 17 considered is 66.85 /USD 1.00 Average conversion

More information

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities

More information

Policies that encourage innovation in middle-income countries

Policies that encourage innovation in middle-income countries December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to

More information

INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE!

INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE! INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE! TOPADUR PHARMA AG a promising Swiss start-up investment Global Medical Need: Diabetes mellitus is one of the major health concerns worldwide.

More information

WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT

WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges

More information

A gateway to academic excellence for Biotech and Pharma

A gateway to academic excellence for Biotech and Pharma A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging

More information

Inaugural Fraunhofer Delaware Technology Summit

Inaugural Fraunhofer Delaware Technology Summit Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu

More information

Antisense Therapeutics Ltd ASX:ANP January 2017

Antisense Therapeutics Ltd ASX:ANP January 2017 Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential

More information

Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO

Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO Developing innovative new medicines for acute and chronic neurological and psychiatric conditions Larry Glass, CEO (lglass@neurenpharma.com) Neuren Pharmaceuticals Created to commercialize University of

More information

Bank of America Merrill Lynch Healthcare Conference. September 13, 2013

Bank of America Merrill Lynch Healthcare Conference. September 13, 2013 Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and

More information

CRO partner in Rx/CDx Co-Development

CRO partner in Rx/CDx Co-Development CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics

More information

Patent : Intellectual Property

Patent : Intellectual Property Patent : Intellectual Property Patent : A set of exclusive rights granted by a sovereign state to an inventor or their assignee for a fixed period of time (up to 20 years) in exchange for the public disclosure

More information

Corporate Presentation. April 2016

Corporate Presentation. April 2016 Corporate Presentation April 2016 1 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

PTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders. March 2018

PTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders. March 2018 PTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders March 2018 Mar-18 Page 1 Forward looking statements within the meaning of The Private Securities Litigation

More information

Life Sciences Practice

Life Sciences Practice Life Sciences Practice The healthcare landscape has recently experienced considerable changes, including highly visible public demands for safer and improved healthcare systems. At the core of this is

More information

For personal use only

For personal use only For personal use only A clinical-stage drug development business Investor Update Dr James Williams February 2016 Agenda today 1. Who we are 2. Snapshot and financials 3. Market and long-term growth strategy

More information

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT

More information

Drug Reposition & Open Innovation Initiatives: potential paths to new therapies and advancing medical science

Drug Reposition & Open Innovation Initiatives: potential paths to new therapies and advancing medical science Duke Law Center for Innovation Policy New Approaches and Incentives in Drug Development Washington D.C., November 22, 2013 Drug Reposition & Open Innovation Initiatives: potential paths to new therapies

More information

TAK-CELERATOR. Introducing a new External R&D Initiative to Accelerate Development of Therapies in Rare Diseases. Patients Partnerships Performance

TAK-CELERATOR. Introducing a new External R&D Initiative to Accelerate Development of Therapies in Rare Diseases. Patients Partnerships Performance TAK-CELERATOR Introducing a new External R&D Initiative to Accelerate Development of Therapies in Rare Diseases Dr Christine Charman Findacure Scientific Conference The Royal College of Nursing, London

More information

ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.

ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded

More information

Around The Clock Therapy Through Continuous Dosing

Around The Clock Therapy Through Continuous Dosing Around The Clock Therapy Through Continuous Dosing DURECT ANNUAL REPORT 2000 CORPORATE MILESTONES Initial Public Offering Completed September 2000 Construction of commercial Around The Clock Therapy Through

More information

leading the way in research & development

leading the way in research & development leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and

More information

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration

More information

The Mochida Pharmaceutical Group s Medium Term Management Plan

The Mochida Pharmaceutical Group s Medium Term Management Plan The Mochida Pharmaceutical Group s 15-17 Medium Term Management Plan This material is an English translation of the press release issued on April 1, 2015 in Japanese, and the Japanese release is given

More information

REIMAGINING DRUG DEVELOPMENT:

REIMAGINING DRUG DEVELOPMENT: Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY

More information

Collaborative Development Financing

Collaborative Development Financing Collaborative Development Financing 14 by Warren Nachlis and Wendy Brasunas The Growth of the Biotechnology Industry Pharmaceutical drug development is a risky and very expensive process. According to

More information

The Innovative Medicines Initiative: Building new models of collaborative research across Europe

The Innovative Medicines Initiative: Building new models of collaborative research across Europe The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused

More information

Conference call transcript for the March 2017 Quarterly Report

Conference call transcript for the March 2017 Quarterly Report ASX ANNOUNCEMENT Conference call transcript for the March 2017 Quarterly Report Sydney Australia, 31 May 2017: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its transcript

More information

On Helix. 02 July Harren Jhoti President & CEO

On Helix. 02 July Harren Jhoti President & CEO On Helix 02 July 2014 Harren Jhoti President & CEO Astex Pharmaceuticals Global developer of small molecule drugs for unmet medical needs Expertise in oncology discovery & development World-class fragment-based

More information

Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection

Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection Douglas Mayers, MD December 11, 2013 1 Idenix: Advancing All-Oral, Pan-Genotypic Combination

More information

INVESTOR PRESENTATION FULL YEAR 2007 RESULTS. February 2008

INVESTOR PRESENTATION FULL YEAR 2007 RESULTS. February 2008 INVESTOR PRESENTATION FULL YEAR 2007 RESULTS February 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may, would,

More information

Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015

Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015 Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, 28-29 September 2015 (PhD) Agenda Key challenges facing the Pharmaceutical Industry 1. Delivering shareholder/stakeholder

More information

The Economics of New Drug Development: Costs, Risks, and Returns

The Economics of New Drug Development: Costs, Risks, and Returns The Economics of New Drug Development: Costs, Risks, and Returns Joseph A. DiMasi, Ph.D. Tufts Center for the Study of Drug Development Tufts University The New England Drug Metabolism Group Spring Meeting

More information

uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value

uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value uniqure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Company Structure Simplified; Manufacturing to be Consolidated into Lexington,

More information

Roche in Australia Innovation Leader

Roche in Australia Innovation Leader Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving

More information

Translational Research through Public-Private Partnerships. 65 th Annual Bohan Lecture. Scott J. Weir, PharmD, PhD 08 October 2011

Translational Research through Public-Private Partnerships. 65 th Annual Bohan Lecture. Scott J. Weir, PharmD, PhD 08 October 2011 Translational Research through Public-Private Partnerships 65 th Annual Bohan Lecture Scott J. Weir, PharmD, PhD 08 October 2011 Drug Focused Translational Research Translational Research Defined by the

More information

Nanotechnology and Advanced Materials for more effective Healthcare

Nanotechnology and Advanced Materials for more effective Healthcare Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics

More information

EU support for Health Research from FP6 to FP7

EU support for Health Research from FP6 to FP7 EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes

More information

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program

BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical

More information

The Aptuit Center for Drug Discovery & Development Verona, Italy

The Aptuit Center for Drug Discovery & Development Verona, Italy The Aptuit Center for Drug Discovery & Development Verona, Italy 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable

More information

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all

More information

TRANSFORMING ETHYPHARM INTO A FULLY FLEDGED SPECIALTY COMPANY BY BUILDING ON OUR STRENGTHS

TRANSFORMING ETHYPHARM INTO A FULLY FLEDGED SPECIALTY COMPANY BY BUILDING ON OUR STRENGTHS TRANSFORMING ETHYPHARM INTO A FULLY FLEDGED SPECIALTY COMPANY BY BUILDING ON OUR STRENGTHS 1 HIGHLIGTHS Ethypharm designs, develops and produces complex drug formulations 166 M global turnover 2013 # 15%

More information

ABPI response to European Commission consultation on advanced therapy medicinal products

ABPI response to European Commission consultation on advanced therapy medicinal products ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal

More information

Technology Development Funding Program Round 3

Technology Development Funding Program Round 3 Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science

More information

Business Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs

Business Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs Business Units Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed an in-house range of APIs and related intermediates. Focusing on chemistries where

More information

Use of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals

Use of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,

More information

Intec. Pharma Unfolding drug delivery solutions. Investor Presentation. Nasdaq: NTEC. June 2017

Intec. Pharma Unfolding drug delivery solutions. Investor Presentation. Nasdaq: NTEC. June 2017 Intec Pharma Unfolding drug delivery solutions Investor Presentation Nasdaq: NTEC June 2017 Forward Looking Statements This presentation by Intec Pharma Ltd. (referred to as we or our ) contains forward-looking

More information

Konica Minolta to Acquire Invicro (US)

Konica Minolta to Acquire Invicro (US) Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September

More information

Disclaimer. 2

Disclaimer.  2 www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content

More information

Corporate Presentation. March 2018

Corporate Presentation. March 2018 Corporate Presentation March 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation

More information

Corporate Overview. June 2017

Corporate Overview. June 2017 Corporate Overview June 2017 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included

More information

Indian CRAMS players to cram in growth: CARE Ratings

Indian CRAMS players to cram in growth: CARE Ratings January, 2015 Credit Perspective : Indian CRAMS Indian CRAMS players to cram in growth: CARE Ratings CARE Ratings expects Indian Contract Research and Manufacturing Services (CRAMS) players to register

More information

The promise of cell therapy for liver diseases: hurdles and success in drug development Beatrice De Vos, MD, PhD, BCPM (CMO PB)

The promise of cell therapy for liver diseases: hurdles and success in drug development Beatrice De Vos, MD, PhD, BCPM (CMO PB) The promise of cell therapy for liver diseases: hurdles and success in drug development Beatrice De Vos, MD, PhD, BCPM (CMO PB) Research Symposium on digestive and liver diseases European Parliament, Brussels

More information

Second Quarter 2016 Financial Results. August 4, 2016

Second Quarter 2016 Financial Results. August 4, 2016 Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking

More information

Alliance for Regenerative Medicine

Alliance for Regenerative Medicine Alliance for Regenerative Medicine Michael Werner Executive Director Alliance for Regenerative Medicine ARM s Focus & Role As the leading global advocate for the regenerative medicine and advanced therapies

More information

Axel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK

Axel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,

More information

Tuberculosis Drug Accelerator

Tuberculosis Drug Accelerator Tuberculosis Drug Accelerator Overview of Activities and Portfolio who, why, what, how, by when and where are we now Steve Berthel 1 What is the Tuberculosis Drug Accelerator? The A is a groundbreaking

More information

SMEs in IMI2 Calls for Proposals

SMEs in IMI2 Calls for Proposals SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative

More information

Adaptive Design for Medical Device Development

Adaptive Design for Medical Device Development Adaptive Design for Medical Device Development A guide to accelerate clinical development and enhance portfolio value Executive Summary In May 2015, the FDA released a draft guidance document regarding

More information

Section I: Pharmaceuticals and Medical Devices

Section I: Pharmaceuticals and Medical Devices SUPPLEMENT on HEALTHCARE INNOVATION Visionary Goals and Recommendations 51th Japan-U.S. Business Conference Japan-U.S. Business Council / U.S.-Japan Business Council November 14, 2014 The R&D-based pharmaceutical

More information

Reduce costs of the early drug development process Increase probality of developing drugs that enter late clinical phases

Reduce costs of the early drug development process Increase probality of developing drugs that enter late clinical phases Aktivitetsplan 5 - Application for Strategic collaboration on joint development and implementation of service offerings between Bioneer A/S and Fraunhofer Institute for Biomedical Engineering (Særskilt

More information

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives

More information

Innovating out of Crisis

Innovating out of Crisis Innovating out of Crisis Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation 1 st June, 2015 Business Fields of Fujifilm Group Digital Camera Photo book Optical devise FY2015/3 Digital minilab

More information

7 Sexual Health.

7 Sexual Health. RESE ARCH & DEVELOPMENT 22 Highlights Signed an agreement with Medicines for Malaria Venture (MMV) to provide MMV with access to the Pfizer library of novel chemical entities to screen for compounds that

More information

Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)

Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Biotech/Patent Licensing

Biotech/Patent Licensing Biotech/Patent Licensing By Jeffrey P. Somers mbbp.com A version of this article appeared in The Journal of Biolaw and Business Vol. 6, No. 3, 2003 CityPoint 230 Third Avenue, 4th Floor Waltham, MA 02451

More information

Goldman Sachs Key Debates In Biosimilars Conference

Goldman Sachs Key Debates In Biosimilars Conference Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during

More information

Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia

Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Published: 07:00 04.10.2007 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Liestal and

More information

Quarterly Report for the Period Ended 31 March 2018

Quarterly Report for the Period Ended 31 March 2018 Quarterly Report for the Period Ended 31 March 2018 Highlights Cash receipts of $617,440 received during the March quarter. Main royalty contributors were the SK-II Power Booster (throughout Asia) and

More information

For personal use only

For personal use only Shareholder Presentation Perth, WA Annual General Meeting 17th November 2016 Global leader in applying proteomics to MedTech ASX: PIQ 1 Disclaimer & forward-looking statements This Presentation is provided

More information

Master List of Professional Electives Course Title Description Credit Hours. Note: This class only meets for the last 7 class periods of the semester.

Master List of Professional Electives Course Title Description Credit Hours. Note: This class only meets for the last 7 class periods of the semester. Course Number PHTH7044 PHRX7064 PHRX704C PHRX706 PHTH8048 PHRX 904 PHRX 904 Master List of Professional Electives Course Title Description Credit Hours Advanced Cardiac Life Support Emphasis (P only) Advanced

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION March 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may, would, could and plan and similar

More information

CURRENT ISSUES IN INTELLECTUAL PROPERTY: A PATIENT PERSPECTIVE

CURRENT ISSUES IN INTELLECTUAL PROPERTY: A PATIENT PERSPECTIVE CURRENT ISSUES IN INTELLECTUAL PROPERTY: A PATIENT PERSPECTIVE Consumer Advocare Network s submission to WHO's Second Public Hearing on Public Health Innovation and Intellectual Property The Consumer Advocare

More information

Handy Gelbard, Director Professor of Neurology, Pediatrics, Microbiology & Immunology and Neuroscience

Handy Gelbard, Director Professor of Neurology, Pediatrics, Microbiology & Immunology and Neuroscience The Center for Neural Development and Disease (will be The Center for NeuroTherapeutics Discovery) Handy Gelbard, Director Professor of Neurology, Pediatrics, Microbiology & Immunology and Neuroscience

More information

Decoding Phase II Clinical Trial Terminations

Decoding Phase II Clinical Trial Terminations Decoding Phase II Clinical Trial Terminations Why Phase II trials are terminated and what can be done to improve Phase II success rates - the most critical inflection point for clinical development Subha

More information

Lilly Research Centre Erl Wood Innovation starts here

Lilly Research Centre Erl Wood Innovation starts here Lilly Research Centre Erl Wood Innovation starts here September 2011 Produced by Eli Lilly and Company Limited Erl Wood Manor, Windlesham, Surrey GU20 6PH www.lilly.co.uk Answers That Matter. Innovation

More information

BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS : TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within

More information

Venture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program. A FasterCures Webinar June 19, 2013

Venture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program. A FasterCures Webinar June 19, 2013 Venture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program A FasterCures Webinar June 19, 2013 What is FasterCures? Founded in 2003, our mission is to save lives by saving

More information

Globalization and Innovation will drive growth

Globalization and Innovation will drive growth JPMorgan Healthcare Conference The New Takeda January 10, 2012 Yasuchika Hasegawa President & CEO 0 Globalization and will drive growth Leading worldwide pharmaceutical company operating in 70 countries

More information

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International

More information

The Innovative Medicines Initiative Socio-economic impacts

The Innovative Medicines Initiative Socio-economic impacts The Innovative Medicines Initiative Socio-economic impacts Pierre Meulien, IMI Executive Director European Innovation Summit European Parliament 08.12.2015 Closed & open innovation Filing Approval HTA

More information

Innovative therapies. FIT Biotech Oy Chief Scientific Officer Santeri Kiviluoto, PhD, BSc (Econ & Bus Adm)

Innovative therapies. FIT Biotech Oy Chief Scientific Officer Santeri Kiviluoto, PhD, BSc (Econ & Bus Adm) Innovative therapies FIT Biotech Oy Chief Scientific Officer Santeri Kiviluoto, PhD, BSc (Econ & Bus Adm) Disclaimer Any forward-looking statements, estimates and calculations included herein, relating

More information